100
Participants
Start Date
April 14, 2015
Primary Completion Date
February 16, 2023
Study Completion Date
February 16, 2023
Mepolizumab
Mepolizumab will be available as lyophilized powder for injection to be reconstituted with sterile water for injection, prior to use. Subjects will be dosed with mepolizumab at a dose of 300 mg which will be administered as three separate 100 mg SC injections every 4 weeks. The injections will be administered into any of the upper arm, thigh or anterior abdominal wall.
Prednisolone
Subjects who require a dose of prednisolone (or equivalent) of 5 mg/day for adequate control of their EGPA will be included.
GSK Investigational Site, Brussels
GSK Investigational Site, New York
GSK Investigational Site, Marseille
GSK Investigational Site, Philadelphia
GSK Investigational Site, Bethesda
GSK Investigational Site, Abingdon
GSK Investigational Site, Bad Bramstedt
GSK Investigational Site, Montpellier
GSK Investigational Site, Fulda
GSK Investigational Site, Mempis
GSK Investigational Site, Saint-Priest-en-Jarez
GSK Investigational Site, Cleveland
GSK Investigational Site, St Louis
GSK Investigational Site, Bron
GSK Investigational Site, Oklahoma City
GSK Investigational Site, Kirchheim -Teck
GSK Investigational Site, Paris
GSK Investigational Site, Freiburg im Breisgau
GSK Investigational Site, Denver
GSK Investigational Site, Murray
GSK Investigational Site, St. George
GSK Investigational Site, Suresnes
GSK Investigational Site, Bellevue
GSK Investigational Site, Hamilton
GSK Investigational Site, Jena
GSK Investigational Site, Kanagawa
GSK Investigational Site, Miyagi
GSK Investigational Site, Portsmouth
GSK Investigational Site, Cambridge
GSK Investigational Site, Leicester
GSK Investigational Site, Boston
GSK Investigational Site, Boston
Lead Sponsor
GlaxoSmithKline
INDUSTRY